Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Consent of parent or legal guardian required~* Chronic HCV infection genotype 2 or 3~* Screening laboratory values within defined thresholds~* PK Lead-in only: all individuals must be treatment naive~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus~* Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)~* Pregnant or nursing females~* Known hypersensitivity to study medication~* Use of any prohibited concomitant medications as within 28 days of the Day 1 visit~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2) (Type: EXPERIMENTAL): Participants between 12 to \< 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
- 12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3) (Type: EXPERIMENTAL): Participants between 12 to \< 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
- 6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2) (Type: EXPERIMENTAL): Participants between 6 to \< 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
- 6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3) (Type: EXPERIMENTAL): Participants between 6 to \< 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
- 3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2) (Type: EXPERIMENTAL): Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
- 3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3) (Type: EXPERIMENTAL): Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete